Scarica l'app Stockscreener
4.68
3.90%
-0.19
Precedente Chiudi:
$4.87
Aprire:
$4.9
Volume 24 ore:
2.81M
Relative Volume:
0.91
Capitalizzazione di mercato:
$792.96M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-234.00
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
+0.00%
1M Prestazione:
-12.03%
6M Prestazione:
+134.00%
1 anno Prestazione:
+692.15%
Intervallo 1D:
$4.605
$4.9811
Intervallo di 1 settimana:
$4.56
$5.11
Portata 52W:
$0.40
$6.35
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.68 | 792.96M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Iniziato | Guggenheim | Buy |
| 2025-09-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
CytomX Therapeutics Hits Day High with Strong 7.48% Intraday Surge - Markets Mojo
CYTOMX THERAPEUTICS Q4 2025 Earnings Preview: Recent $CTMX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
CytomX Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Movement Recap: Is CytomX Therapeutics Inc benefiting from interest rate changes2026 Setups & Step-by-Step Swing Trade Plans - baoquankhu1.vn
How The CytomX Therapeutics (CTMX) Story Is Shifting With Lofty P/E Assumptions And New Targets - Yahoo Finance
Short Squeeze: Is CytomX Therapeutics Inc a good ESG investment2026 Year in Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Attachment - GlobeNewswire
Where CytomX Therapeutics Stands With Analysts - Sahm
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX) and Illumina (ILMN) - The Globe and Mail
CytomX Therapeutics (NASDAQ:CTMX) Receives "Buy" Rating from Guggenheim - MarketBeat
CytomX Therapeutics (CTMX) Analyst Ratings Reiterate 'Buy' Stance | CTMX Stock News - GuruFocus
Earnings Recap: Is CytomX Therapeutics Inc benefiting from interest rate changes2025 Winners & Losers & Low Risk High Reward Ideas - baoquankhu1.vn
Why CytomX Therapeutics Inc. stock is a value investor pickMarket Growth Report & Consistent Profit Trade Alerts - Naître et grandir
Aug Highlights: Can CytomX Therapeutics Inc disrupt its industryWeekly Trading Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Risks Report: Can CytomX Therapeutics Inc disrupt its industryJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Market Fear: Whats the profit margin of CytomX Therapeutics IncWeekly Stock Recap & Precise Swing Trade Alerts - baoquankhu1.vn
Risk Report: Whats the profit margin of CytomX Therapeutics IncJuly 2025 News Drivers & Community Consensus Stock Picks - baoquankhu1.vn
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 - Bitget
CytomX Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Kynam Capital files 5.29% stake in CytomX (NASDAQ: CTMX) - Stock Titan
CTMX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CytomX emerges from masked obscurity | ApexOncoClinical Trials news and analysis - Oncology Pipeline
CytomX Therapeutics Target of Unusually High Options Trading (NASDAQ:CTMX) - MarketBeat
CytomX Therapeutics, Inc. to Announce Full Year 2025 Financial Results on March 16, 2026 - Quiver Quantitative
CTMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CytomX Therapeutics, Inc. (CTMX): Investor Outlook Reveals 55.71% Potential Upside - DirectorsTalk Interviews
CTMXCytomx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Earnings Recap: Is CytomX Therapeutics Inc a good ESG investment2025 Stock Rankings & Proven Capital Preservation Methods - baoquankhu1.vn
CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Is CytomX Therapeutics Inc stock showing strong momentumJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Will CytomX Therapeutics Inc. (6C1) stock rise with strong economyWeekly Trend Recap & Smart Swing Trading Techniques - mfd.ru
Unmasking CytomXA Pioneer In Masked Therapeutics - RTTNews
Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating - Finviz
Is CytomX Therapeutics Inc. stock positioned well for digital economyDip Buying & Real-Time Buy Signal Notifications - mfd.ru
CTMX Should I Buy - Intellectia AI
Is CytomX Therapeutics Inc. (6C1) stock a fit for income portfolios2025 Buyback Activity & Expert Curated Trade Setups - mfd.ru
Will CytomX Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Big Picture & Entry Point Strategy Guides - mfd.ru
Can CytomX Therapeutics Inc. disrupt its industryEarnings Recap Summary & Fast Entry Momentum Alerts - mfd.ru
Market Trends: What hedge funds are buying CytomX Therapeutics Inc2025 Fundamental Recap & AI Enhanced Trading Signals - baoquankhu1.vn
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CytomX Therapeutics, Inc. (CTMX) Investor Outlook: A Biotech Pioneer with a 61.87% Potential Upside - DirectorsTalk Interviews
CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts - MarketBeat
FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares - GuruFocus
CytomX at Guggenheim Summit: Promising CRC Treatment Path By Investing.com - Investing.com Canada
Stock Recap: Is CytomX Therapeutics Inc benefiting from interest rate changes2025 Institutional Moves & Capital Protection Trade Alerts - baoquankhu1.vn
How New Analyst Assumptions Are Rewriting The Story For CytomX Therapeutics (CTMX) - Yahoo Finance
CTMX: Masked ADC shows 28% response in late-line CRC; registrational study planned by 2027 - TradingView
Rally Mode: Can CytomX Therapeutics Inc navigate macro headwindsJuly 2025 PreEarnings & High Yield Equity Trading Tips - baoquankhu1.vn
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX) - The Globe and Mail
Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):